Literature DB >> 9422334

Peptidases in human bronchoalveolar lining fluid, macrophages, and epithelial cells: dipeptidyl (amino)peptidase IV, aminopeptidase N, and dipeptidyl (carboxy)peptidase (angiotensin-converting enzyme).

L Juillerat-Jeanneret1, J D Aubert, P Leuenberger.   

Abstract

The modulation of proteolytic activity is an important factor in regulating the metabolism and function of peptide hormones. In this study, the activities of dipeptidyl (carboxy)peptidase (angiotensin-converting enzyme [ACE]), aminopeptidase N (APN), and dipeptidyl (amino)peptidase IV (DPP IV) were measured in the blood, the human bronchial epithelial and alveolar cells, bronchoalveolar macrophages, and the soluble phase of bronchoalveolar lavage (BAL) samples obtained from normal human volunteers and patients with pulmonary pathologic conditions. BAL fluid expressed ACE activity and very low levels of APN and DPP IV activities in the volunteer population, but higher levels could be measured in samples from patients. In patients, increased APN corresponded to a high granulocyte count, while DPP IV and ACE were associated with a high percentage of lymphocytes. Neither AIDS nor smoking induced an increased level of these enzymes. Immunohistochemical staining of bronchoalveolar smears with anti-human ACE monoclonal antibody showed that only macrophages expressed this enzyme. Enzyme histochemistry for DPP IV and APN showed that all leukocytes expressed these activities. APN, DPP IV, and ACE activities were also found in cell extracts of bronchoalveolar macrophages. In extracts of bronchial epithelial and alveolar cells, only APN and DPP IV activities were detected. Kinetic properties of the soluble enzymes in lavage supernatants were comparable to those of serum enzymes. These results demonstrate that soluble forms of cellular enzymes found in BAL fluid are regulated independently of blood and that different cell types may release these enzymes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9422334      PMCID: PMC7131187          DOI: 10.1016/s0022-2143(97)90110-4

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  32 in total

Review 1.  Protease-antiprotease imbalance: local evaluation with bronchoalveolar lavage.

Authors:  M Luisetti; P D Piccioni; A M Donnetta; A Bulgheroni; V Peona
Journal:  Respiration       Date:  1992       Impact factor: 3.580

Review 2.  Cell-surface peptidases as modulators of growth and differentiation.

Authors:  A J Kenny; M J O'Hare; B A Gusterson
Journal:  Lancet       Date:  1989-09-30       Impact factor: 79.321

3.  Determinants of angiotensin II generation during converting enzyme inhibition.

Authors:  L Juillerat; J Nussberger; J Ménard; V Mooser; Y Christen; B Waeber; P Graf; H R Brunner
Journal:  Hypertension       Date:  1990-11       Impact factor: 10.190

4.  Bronchoalveolar lavage fluid angiotensin-converting enzyme in interstitial lung diseases.

Authors:  U Specks; W J Martin; M S Rohrbach
Journal:  Am Rev Respir Dis       Date:  1990-01

5.  Comparison of the T lymphocyte-dependent induction of angiotensin-converting enzyme and leucine aminopeptidase in cultured human monocytes.

Authors:  M S Rohrbach; A K Conrad
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

6.  Glucocorticoids do not alter peptidase expression on a human bronchial epithelial cell line.

Authors:  D Proud; M C Subauste; P E Ward
Journal:  Am J Respir Cell Mol Biol       Date:  1994-07       Impact factor: 6.914

Review 7.  Angiotensin-converting enzyme inhibitors and their influence on inflammation, bronchial reactivity and cough. A research review.

Authors:  B R Lindgren; R G Andersson
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Sep-Oct

8.  A neutralizing epitope of human immunodeficiency virus type 1 has homologous amino acid sequences with the active site of inter-alpha-trypsin inhibitor.

Authors:  A Koito; T Hattori; T Murakami; S Matsushita; Y Maeda; T Yamamoto; K Takatsuki
Journal:  Int Immunol       Date:  1989       Impact factor: 4.823

9.  Structure-function analysis of angiotensin I-converting enzyme using monoclonal antibodies. Selective inhibition of the amino-terminal active site.

Authors:  S Danilov; E Jaspard; T Churakova; H Towbin; F Savoie; L Wei; F Alhenc-Gelas
Journal:  J Biol Chem       Date:  1994-10-28       Impact factor: 5.157

10.  Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation.

Authors:  I Saiki; H Fujii; J Yoneda; F Abe; M Nakajima; T Tsuruo; I Azuma
Journal:  Int J Cancer       Date:  1993-04-22       Impact factor: 7.396

View more
  10 in total

Review 1.  Collectins and cationic antimicrobial peptides of the respiratory epithelia.

Authors:  B Grubor; D K Meyerholz; M R Ackermann
Journal:  Vet Pathol       Date:  2006-09       Impact factor: 2.221

Review 2.  The expression of proline-specific enzymes in the human lung.

Authors:  Gwendolyn Vliegen; Tom K Raju; Dirk Adriaensen; Anne-Marie Lambeir; Ingrid De Meester
Journal:  Ann Transl Med       Date:  2017-03

3.  Regulation of expression and function of dipeptidyl peptidase 4 (DP4), DP8/9, and DP10 in allergic responses of the lung in rats.

Authors:  Jutta Schade; Michael Stephan; Andreas Schmiedl; Leona Wagner; André J Niestroj; Hans-Ulrich Demuth; Nadine Frerker; Christian Klemann; Kerstin A Raber; Reinhard Pabst; Stephan von Hörsten
Journal:  J Histochem Cytochem       Date:  2007-10-29       Impact factor: 2.479

4.  Chemokine (C-C Motif) receptor 1 is required for efficient recruitment of neutrophils during respiratory infection with modified vaccinia virus Ankara.

Authors:  Philip J R Price; Bruno Luckow; Lino E Torres-Domínguez; Christine Brandmüller; Julia Zorn; Carsten J Kirschning; Gerd Sutter; Michael H Lehmann
Journal:  J Virol       Date:  2014-07-09       Impact factor: 5.103

5.  Toxicity of orally inhaled drug formulations at the alveolar barrier: parameters for initial biological screening.

Authors:  Eleonore Fröhlich
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

Review 6.  In Vitro Models for Studying Entry, Tissue Tropism, and Therapeutic Approaches of Highly Pathogenic Coronaviruses.

Authors:  Saeid Najafi Fard; Linda Petrone; Elisa Petruccioli; Tonino Alonzi; Giulia Matusali; Francesca Colavita; Concetta Castilletti; Maria Rosaria Capobianchi; Delia Goletti
Journal:  Biomed Res Int       Date:  2021-06-21       Impact factor: 3.411

7.  Dipeptidyl Peptidase 4 Distribution in the Human Respiratory Tract: Implications for the Middle East Respiratory Syndrome.

Authors:  David K Meyerholz; Allyn M Lambertz; Paul B McCray
Journal:  Am J Pathol       Date:  2015-11-18       Impact factor: 4.307

8.  Reduction of soluble dipeptidyl peptidase 4 levels in plasma of patients infected with Middle East respiratory syndrome coronavirus.

Authors:  Kyung-Soo Inn; Yuri Kim; Abdimadiyeva Aigerim; Uni Park; Eung-Soo Hwang; Myung-Sik Choi; Yeon-Sook Kim; Nam-Hyuk Cho
Journal:  Virology       Date:  2018-03-26       Impact factor: 3.616

9.  Functional Roles for CD26/DPP4 in Mediating Inflammatory Responses of Pulmonary Vascular Endothelial Cells.

Authors:  Yukiko Takahashi; Takeshi Kawasaki; Hironori Sato; Yoshinori Hasegawa; Steven M Dudek; Osamu Ohara; Koichiro Tatsumi; Takuji Suzuki
Journal:  Cells       Date:  2021-12-11       Impact factor: 6.600

10.  Development of new in vitro models of lung protease activity for investigating stability of inhaled biological therapies and drug delivery systems.

Authors:  Arcadia Woods; Teodora Andrian; Gemma Sharp; Elif Melis Bicer; Kalliopi-Kelli A Vandera; Ayasha Patel; Ian Mudway; Lea Ann Dailey; Ben Forbes
Journal:  Eur J Pharm Biopharm       Date:  2019-11-20       Impact factor: 5.571

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.